We are live on !
Find out more
Mariner Portfolio holdings
AUM
$95.2B
Turnover
23.58%
1-Year Est. Return
32.92%
This Fund
S&P 500
This Quarter Est. Return
-0.96%
1 Year Est. Return
+32.92%
3 Year Est. Return
+93.86%
5 Year Est. Return
+109.77%
10 Year Est. Return
+319.92%
AUM
$85.7B
AUM Growth
+$1.66B
(+2%)
Cap. Flow
+$4.07B
Cap. Flow % of AUM
Cap. Flow %
4.75%
Top 10 Holdings %
Top 10 Hldgs %
27.24%
Holding
3,909
New
385
Increased
1,802
Reduced
1,276
Closed
364
Avg Time Held
3.2
years
Top 10 Avg Time Held
4.1
years
Top 20 Avg Time Held
5.4
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apollo Global Management
APO
|
+$274M |
| 2 |
iShares 3-7 Year Treasury Bond ETF
IEI
|
+$184M |
| 3 |
Microsoft
MSFT
|
+$172M |
| 4 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$170M |
| 5 |
iShares Core US Aggregate Bond ETF
AGG
|
+$169M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 7-10 Year Treasury Bond ETF
IEF
|
+$179M |
| 2 |
T-Mobile US
TMUS
|
+$162M |
| 3 |
ProShares Ultra Semiconductors
USD
|
+$135M |
| 4 |
ServiceNow
NOW
|
+$128M |
| 5 |
Abbott
ABT
|
+$126M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.33% |
| 2 | Technology | 21.37% |
| 3 | Financials | 7.66% |
| 4 | Healthcare | 5.22% |
| 5 | Consumer Discretionary | 5.2% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3476
Lucid Diagnostics
LUCD
$91.3M
| $24.3K | ﹤0.01% |
21,153
+7,293
| +53% | +$9.28K |
2025 Q4
1 quarter
|
|
3477
Cardiff Oncology
CRDF
$70.1M
| $23.4K | ﹤0.01% |
+14,451
| New | +$29.7K |
2026 Q1
0 quarters
|
|
|
NVX
3478
NOVONIX
NVX
$53.6M
| $22.7K | ﹤0.01% |
3,291
+1,539
| +88% | +$15K |
2025 Q4
1 quarter
|
|
3479
Veritone
VERI
$54.9M
| $22.5K | ﹤0.01% |
+11,419
| New | +$38.6K |
2026 Q1
0 quarters
|
|
3480
Kaltura
KLTR
$211M
| $22.4K | ﹤0.01% |
+18,333
| New | +$26.1K |
2026 Q1
0 quarters
|
|
3481
Douglas Elliman
DOUG
$135M
| $21.6K | ﹤0.01% |
+13,194
| New | +$30.6K |
2026 Q1
0 quarters
|
|
3482
INmune Bio
INMB
$43.6M
| $21.5K | ﹤0.01% |
19,043
+8,793
| +86% | +$12.5K |
2025 Q2
3 quarters
|
|
3483
New Found Gold
NFGC
$619M
| $20.8K | ﹤0.01% |
+10,745
| New | +$28.8K |
2026 Q1
0 quarters
|
|
3484
PSQ Holdings
PSQH
$12.3M
| $20.4K | ﹤0.01% |
2,566
-5
| -0.2% | -$59 |
2023 Q3
10 quarters
|
|
3485
Lineage Cell Therapeutics
LCTX
$247M
| $19.8K | ﹤0.01% |
12,514
-584
| -4% | -$985 |
2022 Q3
14 quarters
|
|
3486
Accuray
ARAY
$18.6M
| $19.1K | ﹤0.01% |
49,226
+21,624
| +78% | +$13.4K |
2025 Q2
3 quarters
|
|
3487
Nerdy
NRDY
$52.4M
| $19.1K | ﹤0.01% |
+1,559
| New | +$22.4K |
2026 Q1
0 quarters
|
|
3488
Definitive Healthcare
DH
$107M
| $18.7K | ﹤0.01% |
+15,241
| New | +$26.5K |
2026 Q1
0 quarters
|
|
3489
New Era Energy & Digital Inc Warrants
NUAIW
$10.1M
| $18.2K | ﹤0.01% |
10,000
| – | – |
2025 Q3
2 quarters
|
|
3490
DocGo
DCGO
$26.9M
| $17.7K | ﹤0.01% |
+28,073
| New | +$21.1K |
2026 Q1
0 quarters
|
|
3491
MIRA Pharmaceuticals
MIRA
$26.6M
| $17.7K | ﹤0.01% |
16,500
| – | – |
2024 Q4
5 quarters
|
|
3492
Lexicon Pharmaceuticals
LXRX
$676M
| $17.3K | ﹤0.01% |
+11,072
| New | +$16.1K |
2026 Q1
0 quarters
|
|
|
NAKA
3493
Nakamoto Inc
NAKA
$128M
| $16.9K | ﹤0.01% |
+1,917
| New | +$24.3K |
2026 Q1
0 quarters
|
|
3494
Paramount Gold Nevada
PZG
$91.4M
| $16.6K | ﹤0.01% |
+10,011
| New | +$18.9K |
2026 Q1
0 quarters
|
|
3495
Nauticus Robotics
KITT
$1.56M
| $15.5K | ﹤0.01% |
+648
| New | +$26.4K |
2026 Q1
0 quarters
|
|
3496
Tenaya Therapeutics
TNYA
$85.4M
| $15.2K | ﹤0.01% |
22,000
-71
| -0.3% | -$52 |
2024 Q4
5 quarters
|
|
3497
BARK
BARK
$69.8M
| $14.7K | ﹤0.01% |
1,451
+864
| +147% | +$13.3K |
2025 Q2
3 quarters
|
|
3498
Arbe Robotics
ARBE
$59M
| $14.4K | ﹤0.01% |
23,627
-2,800
| -11% | -$2.91K |
2025 Q1
4 quarters
|
|
|
FFAI
3499
Faraday Future Intelligent Electric
FFAI
$4.96M
| $14.4K | ﹤0.01% |
+349
| New | +$36.1K |
2026 Q1
0 quarters
|
|
3500
Pulmonx
LUNG
$76.4M
| $14.3K | ﹤0.01% |
+11,067
| New | +$18.3K |
2026 Q1
0 quarters
|
|
Similar funds
Mariner's Q1 2026 Portfolio in Review
As of Q1 2026, Mariner held 3,909 positions worth $85.7B, up 2% from $84B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Mariner deployed $4.07B of net new capital in Q1 2026, opening 385 new positions and adding to 1,802 existing holdings. Its largest new stake was BNY Mellon Dynamic Value ETF: 960,263 shares worth $28.5M.
By sector, the portfolio is most concentrated in Miscellaneous at 43% of assets, up from 43% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was iShares 7-10 Year Treasury Bond ETF, an estimated $179M trimmed.
- Mariner's largest Q1 2026 buy was BNY Mellon Dynamic Value ETF: 960,263 shares worth $28.5M.
- Mariner added most to Apollo Global Management in Q1 2026, an estimated $274M increase.
- Mariner's biggest Q1 2026 reduction was iShares 7-10 Year Treasury Bond ETF, cutting an estimated $179M.
- Mariner fully exited Exact Sciences in Q1 2026, selling an estimated $11.1M.
- Mariner's ten largest holdings make up 27% of its $85.7B portfolio in Q1 2026.
- Mariner opened 385 new positions and closed 364 in Q1 2026.
- Mariner's portfolio value rose 2% quarter-over-quarter to $85.7B.
Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.